Last reviewed · How we verify

pegylated interferon

Replicor Inc. · FDA-approved active Small molecule Quality 5/100

pegylated interferon is a Small molecule drug developed by Replicor Inc.. It is currently FDA-approved. Also known as: pegylated interferon alpha 2a, Pegasys(R), Pegasys, Pegylated interferon (PegIFN), Pegintron.

At a glance

Generic namepegylated interferon
Also known aspegylated interferon alpha 2a, Pegasys(R), Pegasys, Pegylated interferon (PegIFN), Pegintron, PegIntron
SponsorReplicor Inc.
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about pegylated interferon

What is pegylated interferon?

pegylated interferon is a Small molecule drug developed by Replicor Inc..

Who makes pegylated interferon?

pegylated interferon is developed and marketed by Replicor Inc. (see full Replicor Inc. pipeline at /company/replicor-inc).

Is pegylated interferon also known as anything else?

pegylated interferon is also known as pegylated interferon alpha 2a, Pegasys(R), Pegasys, Pegylated interferon (PegIFN), Pegintron, PegIntron.

What development phase is pegylated interferon in?

pegylated interferon is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing